Proprietary Technology
The Mirai™ Platform
Mirai™ is a patented capsule-based dry-powder inhalation architecture that opens the capsule rather than piercing it. The opened capsule is held stationary and becomes part of the airflow pathway.
Designed for Patients, Built for Performance
The Mirai™ inhaler represents a new approach to capsule-based dry powder inhalation. Our global design addresses the key limitations of existing devices while maintaining the established reliability of capsule delivery.
Granted Patent Protection
Device patents granted in the US and 38 European countries - one design for global markets, simplifying regulatory pathways and reducing costs.
Low Resistance
Designed for patients with limited inspiratory capacity - elderly COPD patients and pediatric populations.
Designed for Cost-Effective Manufacture
Efficient design and a manufacturing partnership are intended to deliver meaningful cost advantages.
Modern, Patient-Friendly Design
Sleek, pocket-sized form factor designed to encourage everyday use and support compliance.
The Mirai™ Difference
Most established reusable capsule inhalers rely upon piercing or cutting the capsule. Mirai™ uses a fundamentally different capsule-opening architecture.
The Mirai™ Approach
- Pulls capsule apart - no piercing
Designed to avoid capsule piercing and the associated risk of piercing-derived capsule fragments
- Stationary capsule = consistent dosing
Capsule remains fixed during inhalation - predictable, uniform delivery
- 100% plastic - fully washable
No metal components means easy cleaning and extended reusability
Traditional Capsule Inhalers
- Piercing creates particulates
Metal pins puncture capsules, creating fragments that patients may inadvertently inhale
- Spinning capsule = inconsistent dosing
Capsule spins during inhalation - delivery varies based on inspiratory force
- Steel components limit durability
Metal parts prevent washing, limiting reusability and hygiene
Device Specifications
Inhaler Type
Passive (no electronics), capsule-based DPI
Capsule Compatibility
Multi-size (size 0 and size 3)
Airflow Resistance
Designed for low resistance
Capsule Mechanism
Pull-apart release - no piercing, stationary during inhalation
Materials
100% plastic (ABS + PC) - no metal; intended to be fully washable
Form Factor
Production-intent pocket-sized design
Patent Status
Granted - United States + 38 European countries
Development Status
The core Mirai™ capsule-opening and aerosol-delivery architecture has been embodied in a purpose-built development chassis and independently evaluated at Intertek. Production tooling, complete-device assembly and formal design verification remain part of the next industrialisation phase.
The Integrated Advantage
Unlike competitors who specialize in either devices or formulations, Knightpoint Group controls both - enabling optimized system performance for combination products.
Device Expertise
- Patented inhaler design
- Global manufacturing partnership
- Device performance optimization
Formulation Science
- Triple-combination expertise
- ICS/LAMA/LABA programs
- ICS/LAMA/LABA formulation know-how
Broad Therapeutic Potential
The Mirai™ platform is designed for a broad range of inhaled therapeutic applications.
Complex and differentiated inhaled generics.
Dry-powder alternatives to selected pMDI products.
Rescue and rapid-onset therapies.
Biologics and peptides, including potential GLP-1 applications.
Vaccines, antivirals and anti-infectives.
CNS, oncology and systemic pulmonary delivery.
Interested in Strategic Ownership or Development of Mirai™?
The Mirai™ device platform - with granted IP in the United States and 38 European countries - is available for strategic acquisition or licensing. Contact our business development team.
Discuss a Strategic Transaction